MedWatch - Natalizumab (marketed as Tysabri) - FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML)

ROCKVILLE, Md., Sept. 22, 2009--FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri. Tysabri was approved by the FDA for the treatment of relapsing forms of multiple sclerosis (MS)...